Study Shares Promising Data that DMT May Treat Major Depressive Disorder
Phase IIa clinical trial exploring the use of DMT for Major Depressive Disorder has revealed some promising results.
small pharma
The Biggest Psychedelic News Stories This Week – March 10
Health Canada’s decision to deny a terminally ill Saskatoon man permission to continue psychedelic psilocybin therapy has drawn a lot of attention and criticism from psychedelic advocates.
The Biggest Psychedelic News Stories This Week – February 24
This week witnessed a wave of US states dwelling on psychedelic policies to be included in voting agendas, while cutting-edge DMT research is being subsidized for mental health studies.
A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 Trial
Compass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research
5 Next-Generation Psychedelics Entering Clinical Trials This Year
Modernized psychedelic medicine is coming, whether you like it or not, so here are five of the most exciting next-generation psychedelics on the horizon.
5 Most Important Psychedelic Clinical Trials in 2022
Here’s why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
Is Small Pharma a Good Psychedelic Stock Investment?
Our resident Psychedelic Investor James Hallifax looks at the pros and cons of this Canadian-based company developing DMT for therapeutic use.
Psychedelic Business Spotlight- March 11
This week in psychedelic business news: Small Pharma prepares big DMT studies; Health Canada approves a psilocybin PTSD study.
Psychedelic Business Spotlight: October 22
This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field Trip Health expands its clinical presence in the US; and another psychedelic pharmaceuticals company prepares for the Nasdaq.
Psychedelic Business Spotlight: September 24, 2021
This week in psychedelic business news: two patents may revolutionize the medical application of psychedelic compounds; DMT and ibogaine clinical trials show promise; and stock news for psychedelic investors.
End of content
End of content